RO5126766: all 26 studies that test it

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic AdenocarcinomaNot yet recruitingNCT07824960Phase 1/2
• Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorNot yet recruitingNCT07743554Phase 2
• Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingNCT07318324Phase 1
• Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaRecruitingNCT07126158Phase 2
• Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingNCT06495125Phase 2
• Avutometinib and Defactinib in Diffuse Gastric CancerRecruitingNCT06487221Phase 2
• A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingNCT06394804Phase 2
• Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingNCT06369259Phase 2
• A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT06072781Phase 3
• A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingNCT06007924Phase 2
• VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingNCT05608252Phase 1/2
• A Phase 2 Study of Avutometinib (VS-6766) Plus DefactinibRecruitingNCT05512208Phase 2
• Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal MelanomaTerminatedNCT04720417Phase 2Results posted
• A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsActive, not recruitingNCT06682572Phase 2
• A Study of Avutometinib for People With Solid Tumor CancersActive, not recruitingNCT06104488Phase 1
• Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaActive, not recruitingNCT05798507Early Phase 1
• A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerActive, not recruitingNCT05787561Phase 2
• Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerActive, not recruitingNCT05669482Phase 1/2
• Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsCompletedNCT05375994Phase 1/2
• Food Effect of VS-6766 in Healthy Adult SubjectsCompletedNCT05187169Phase 1
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingNCT05074810Phase 1/2
• A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS MutationActive, not recruitingNCT04625270Phase 2
• A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerCompletedNCT04620330Phase 2
• Phase I Trial of Defactinib and VS-6766.Active, not recruitingNCT03875820Phase 1
• RO5126766 for Patients With Advanced KRAS-Mutant Lung CancerCompletedNCT03681483Phase 1
• A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.CompletedNCT00773526Phase 1

← RO5126766 overview